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Adrenomedullin (AM) is a multifunctional peptide expressed in the normal and malignant prostate, and in prostate cancer cells.
To elucidate the potential role of AM in prostate cancer, we have transfected the human AM gene into PC-3, DU 145, and LNCaP
prostate cancer cells. Northern blot, Western blot, and radioimmunoassay techniques conﬁrmed an increase in the synthesis and
secretion of the 6 kDa mature peptide, in the AM-transfected clones. Proliferation and cell cycle assays demonstrated that AM over-
expression inhibited cell proliferation in PC-3 and LNCaP cells through a G0/G1 cell cycle arrest, but not in DU 145 cells. In vivo
growth assays also conﬁrmed that, at least in PC-3, AM produced a very signiﬁcant reduction of tumor volume. In addition, the
three cell lines expressed the CL/RCP/RAMP-2 receptor complex by RT-PCR, which suggests that AM peptide acts through an
autocrine loop in prostate cancer cells. Although cAMP elevation is the most common pathway involved in AM signalling, stim-
ulation of PC-3, DU 145, and LNCaP with synthetic AM did not increase intracellular cAMP. However, short-term stimulation
of PC-3 cells with synthetic AM increased ERK1/2 activation. On the contrary, long-term stimulation, or AM overexpression,
caused a reduction in the basal activation of ERK1/2. In summary, our results demonstrate that AM (either overexpressed or exo-
genously added) causes an inhibition of prostate cancer cell growth. This inhibition does not depend on changes in intracellular
cAMP levels, but may be related to ERK1/2 activation.
 2004 Elsevier Inc. All rights reserved.
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cancer mortality among men in the US [1]. Although
some of the molecular mechanisms involved in pros-
tate cancer progression have been elucidated, the
development of the disease is largely unknown. In
addition, the limited success of prostate cancer thera-
pies requires that additional targets for therapy be
identiﬁed and tested. We and others have previously0006-291X/$ - see front matter  2004 Elsevier Inc. All rights reserved.
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E-mail address: acalvo@unav.es (A. Calvo).described the expression of adrenomedullin (AM), a
52-aminoacid peptide isolated from a pheochromocy-
toma [2], in the normal and malignant prostate [3–5].
Although numerous functions have been attributed
to AM in diﬀerent organs, such as vasodilation, bron-
chodilation, hormone secretion control, and regulation
of cell growth [6], the role of AM in the prostate and
in prostate carcinoma is not well understood. The
eﬀect of AM on cell growth has been studied in sev-
eral cell types. AM stimulates proliferation of zona
glomerulosa cells, skin ﬁbroblasts, glioblastoma, and
lung cancer cells [6,7]. However, AM causes growth
inhibition of myocytes, cardiac ﬁbroblasts, vascular
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angial cells [6,7]. The reason for this opposite eﬀect on
cell growth depending upon the cell type is still to be
determined.
Three diﬀerent AM receptors have been described:
L1, RDC1, and the calcitonin receptor-like receptor
(CL), which belong to the seven transmembrane G-cou-
pled receptors [6]. Among these, recent publications
show that CL is the most important and widespread
receptor involved in AM function. CL requires the
presence of certain regulatory proteins with a single
transmembrane domain known as receptor activity-
modifying proteins (RAMPs) [8]. CL acts as a calcitonin
gene related protein (CGRP) or AM receptor, when
coupled with RAMP-1. However, the complex binds
CGRP with much more aﬃnity than AM [8]. RAMP-
2 or RAMP-3 coupled with CL binds speciﬁcally to
AM [8]. The receptor component protein (RCP) is
responsible for the initiation of the intracellular trans-
duction of the signal [9,10].
The activation of the receptor by AM has com-
monly been linked to elevation of cAMP [6]. However,
recent studies have shown that alternative intracellular
pathways may act in AM signalling. These include,
among others, elevation of Ca+2 levels [11], activation
of the cGMP-NO pathway [6,12,13] or the involvement
of the mitogen-activated protein kinases (MAPKs)
[14,15].
In order to clarify the role of AM in prostate can-
cer, we previously generated PC-3 cell clones which
overexpressed the rat AM gene, and found, as a re-
sult, a striking cell growth inhibition both in vitro
and in vivo in these clones [16]. In this study we have
expanded the study to other prostate cancer cells
(LNCaP and DU 145) and analyzed the eﬀect of hu-
man AM overexpression. We show here that, indeed,
increased expression of AM or exogenous treatment
with the AM peptide produce cell growth inhibition
in prostate cancer cells. We also demonstrate that
prostate cancer cells express AM receptors, which
suggests an autocrine loop for AM activity. Intracel-
lular signalling seems to involve ERK1/2 activation
rather than an increase in cAMP levels in prostate
cells.Materials and methods
Vector design. The pSecTagB plasmid (Invitrogen, Carlsbad, CA)
containing the complete sequence of the human AM (hAM) was kindly
donated by Dr. Alfredo Martı´nez (NCI, NIH, Bethesda, MD). hAM
was then subcloned into the pcDNA3.1/Hygro plasmid (Invitrogen) by
PCR, using the following primers: CATGCTAGCGCCACCATGA
AGCTGGTTTCCGTC (forward), and CTAGGATCCCTAAGGAA
AGTGGGGAGCACT (reverse), under the following conditions:
94 C, 45 s; 55 C, 45 s; and 72 C, 75 s (35 cycles). The PCR product
included sequences for the restriction enzymes NheI (at the 5 0 position)and BamHI (at the 3 0 end), and for the Kozak sequence (GCCACC)
(at the 5 0 end).
Cell culture, proliferation, and cell cycle analysis. Prostate cancer
cell lines (PC-3, DU 145, and LNCaP) were cultured in 5% CO2 at
37 C in RPMI 1640 medium with Glutamax-I (Invitrogen) supple-
mented with 10% fetal calf serum (FCS; Invitrogen), 100 U/ml pen-
icillin, and 100 lg/ml streptomycin (Invitrogen). Cells were stably
transfected with the pcDNA3.1/Hygro plasmid containing hAM or
the plasmid alone (as a control). Transfections were done with Fu-
gene 6 (Roche, Penzberg, Germany) following the manufacturers
protocol. Selection of cell clones was performed with 150 lg/ml
hygromycin B (Invitrogen). Up to 20 individual clones per cell line
were randomly chosen to study AM expression. In the case of
LNCaP, we could not establish cell clones with stable expression of
AM. Cell clones lost expression of AM after several days in culture,
and therefore the experiments were conducted with transiently
transfected cells.
Proliferation assays of the stably transfected clones were conducted
in 96-well plates with 1000 or 1500 cells/well in serum free medium.
After 24 h, 10% FCS or conditioned medium from PC-3 cells was
added to the cultures and cell viability was assessed for the following 5
days using the MTT assay (Roche). Proliferation assays were also
performed in parental cell lines by daily addition of the human AM
(hAM) peptide (Peninsula–Bachem, San Carlos, CA) at concentrations
ranging from 0.1 to 1000 nM. For these experiments, cells were cul-
tured with low amount of FCS (1%). We have previously tested that
cells cultured in 1% FCS maintain considerable good growth capa-
bilities, while reduction of the serum below 0.5–1% leads to signiﬁcant
cell growth decrease (stress conditions).
For cell cytometry analysis, synchronized cells were grown in
complete medium for 24 h, collected, and processed with DNA Prep
Coulter (Beckman–Coulter, Fullerton, CA). Cells were analyzed in a
FacsCalibur ﬂow cytometer with an excitation wavelength of 488 nm.
Anchorage independent growth in soft agar was also evaluated as
previously described [16]. Representative photographs were taken with
a Leica phase contrast microscope and are occupied by the colonies
was calculated by image analysis (analySYS 3.0, Soft Imaging System,
GmbH, Munster, Germany).
In vivo tumor growth. PC-3 cell clones were subcutaneously injected
(1 · 106 cells per mouse) in BALB/c athymic nude mice (4-week-old
males, 5 mice per group). Tumor size was measured weekly and vol-
umes were calculated using the previously described formula
V = (w2 · l)/2 [17]. Mice were sacriﬁced when tumors reached 1 cm3, or
5 weeks after the initiation of the experiment. All mice were treated in
accordance with the guidelines for the Animal Care Ethics Comission
of our institution (Universidad de Navarra) under an approved animal
protocol.
Northern blot and RT-PCR. Total RNA was obtained with the
Ultraspec RNA Kit (Biotecx, S. Loop E. Houston, TX) following the
manufacturers instructions. Northern blot analysis for AM and S9
mRNA was carried out as previously described [18]. One microgram of
DNAse-treated RNA was reversed transcribed into cDNA using the
First Strand SuperScript II RT kit (Invitrogen). For PCR ampliﬁca-
tions, a Perkin–Elmer 2400 thermocycler was used, and PCR products
were run through 1% agarose gels and scanned with Gelprinter SuperII
(Tecnologı´a para Diagno´stico e Investigacio´n, Madrid, Spain). The se-
quence of the primers and melting temperatures used for the PCR are
shown in Table 1. Thirty-ﬁve cycles of PCR were used for the
ampliﬁcation.
Western blot and RIA. Soluble proteins were extracted with RIPA
buﬀer for AM detection or with a speciﬁc lysis buﬀer (25 mM sodium
b-glycerolphosphate, 1 mM sodium orthovanadate, 25 mM NaF,
1 mM Na2P3O4, 1% Triton X-100, 0.05% sodium deoxycholate, 1 mM
benzamidine, 10% glycerol, 0.1% b-mercaptoethanol, 0.01% SDS,
5 mM EDTA, and 5 mM EGTA, all from Sigma) for phosphorylated
protein detection. Both extraction buﬀers contained a cocktail of pro-
tease inhibitors (Complete; Roche Diagnostics, Penzberg, Germany).
Table 1
Sequence of the primers and melting temperatures for the ampliﬁcation by RT-PCR of AM, CL, RCP, RAMPs(1–3), and b-actin, in PC-3, DU 145,
LNCaP, and their cell transfectants
Gene name GenBank Accession No. Primer sense Sequence (5 0 ﬁ 3 0) Position Melting T
AM D14874 S AAGAAGTGGAATAAGTGGGCT 250 55
AS TGTGAACTGGTAGATCTGGT 540
CL U17473 S TGCTCTGTGAAGGCATTTAC 1159 63
AS CAGAATTGCTTGAACTCTC 1655
RCP AF073792 S TGGGCAAGAGAACTTGAACA 111 60
AS TTCCACGATCAGCTGGATCT 306
RAMP1 NM005855 S GAGACGCTGTGGTGTGACTG 189 61
AS TCGGCTACTCTGGACTCCTG 614
RAMP2 AJ001015 S GGACGGTGAAGAACTATGAG 235 60
AS ATCATGGCCAGGAGTACATC 517
RAMP3 AJ001016 S TGGAAGTGGTGCAACCTGTC 189 63
AS CACGGTGCAGTTGGAGAAGA 347
b-Actin BC001301 S TCCATCGTCCACCGCAATG 1169 55
AS TTGTGAACTTTGGGGGATGCTC 1398
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protein assay kit; Pierce, Rockford, IL, USA) and 60 lg of total sol-
uble proteins was separated by SDS–PAGE in 4–12% Bis–Tris poly-
acrylamide pre-cast gels (NuPage, Invitrogen). Electrophoresis was
performed in Mes buﬀer in the presence of 5% of 2-b-mercaptoethanol
for 45 min at 200 V. Proteins were then transferred to a 0.22 lm
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) at 30 V for
1 h, and membranes were stained with Ponc¸eau solution. Blots were
then incubated for 2 h at RT in blocking solution (Tropix, Bedford,
MA, USA). AM detection was conducted as previously described [5]
using a polyclonal antiserum raised in rabbit that recognizes the
amidated AM22–52 synthetic human sequence, at 1:1000 dilution. The
amidated-AM22–52 peptide was used for the absorption controls, at a
concentration of 10 lM. Phosphorylated and total ERK1/2 antisera
(Cell Signalling, Beverly, MA, USA) were used at a 1:1000 dilution.
After incubation with the AP-conjugated anti-rabbit secondary anti-
body (1:20,000 dilution), a chemoluminescence kit (Tropix) was used
for visualization.
Cell supernatants were collected after centrifugation (12,000g, at
4 C, 30 min) and concentration of AM was measured by RIA anal-
ysis, as previously described [16]. A volume of 0.1 ml of medium, or
standard AM (Phoenix Pharmaceuticals, Mountain View, CA) was
incubated for 18 h at 4 C with 0.1 ml of primary antibody. After
incubation, 0.1 ml of 125I-AM was added (10,000 cpm) and the mixture
was incubated at 4 C for 18 h. Bound tracer was separated by poly-
ethylene glycol-facilitated precipitation with goat anti-rabbit serum
and normal rabbit serum. The supernatant was aspirated and radio-
activity of the pellets was determined with a DPC Gambyt CR c
counter.
Measurement of total cAMP. The Biotrak cAMP enzyme immu-
noassay kit (Amersham, UK) was used following the manufacturers
instructions. Cells (50,000–75,000) were seeded in 24-well plates. After
overnight incubation, wells were washed three times with serum- and
antibiotic-free medium, and blocked for 15 min in 1% BSA and
104 M isobutylmethylxanthine (both from Sigma). Cells were then
supplemented with synthetic AM in doses ranging from 1 nM to 1 lM
and incubated at 37 C for 10 min. One micromolar of forskolin
(Sigma, St. Louis, MO) was used as a control. Treatments were
stopped with a lysis buﬀer provided by the kit and plates were ﬁnallyread at 450 nm in a Multiskan Ascent ELISA plate reader
(Labsystems).Results
Transfected prostate cancer cells produce and secrete
mature AM peptide
PC-3 and DU 145 prostate cancer cells were stably
transfected with an expression vector containing the
complete coding sequence for the hAM gene. Up to 20
clones of each cell line were isolated and tested for
hAM mRNA and protein expression, and four PC-3
clones (hAM12, hAM22, hAM31, and hAM32), and
DU 145 clones (hAM5, hAM6, hAM9, and hAM11)
were selected for further studies. In the case of LNCaP,
since it was not possible to obtain stable AM-expressing
clones (as explained in Materials and methods), all the
experiments were conducted with transient transfec-
tions. Fig. 1A shows AM mRNA expression of the
parental or transfected cells. An intense band of 0.8 kb
corresponding to the expression of exogenous AM
mRNA was found in the transfected clones. Both paren-
tal and transfected cells showed a faint band of 1.4 kb,
corresponding to the endogenous AM mRNA, which
was also observed in the control H157 lung cell line [19].
AM protein production was studied by Western blot
(Fig. 1B). Only cell lysates from the AM-transfected
clones showed the 6 kDa band corresponding to the
AM mature peptide, which was also observed in the bo-
vine adrenal medulla (M.Ad.) used as a control [20].
Remarkably, PC-3 and DU 145 cell clones with high
Fig. 1. Characterization of AM expression. (A) Northern blots in the upper panels show a faint band for the endogenous AM mRNA (1.4 kb) and a
strong band corresponding to the ectopic hAMmRNA expression (0.8 kb), which is exclusively found in AM-transfected cells. RNA from H157 cells
(a lung cancer cell line) was used as a positive control. In the lower panels, hybridization for S9 mRNA was used as an internal control. (B) Western
blot for AM only shows the 6 kDa band corresponding to the mature AM peptide, in the cells transfected with AM. Bovine adrenal medulla (M.Ad.)
was used as positive control for AM and b-actin as a loading control. Both experiments were performed three times with diﬀerent RNA and protein
extracts.
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also showed high expression of AM peptide (Fig. 1B).
To determine whether AM was secreted into the cell
culture media we performed RIA analysis (Table 2).
Overexpression of AM caused a very signiﬁcant in-
crease in the levels of secreted AM peptide, in the three
cell lines analyzed. This increase, however, was not
homogeneous in all the cell clones. The PC-3 clone
hAM32 showed the highest amount of secreted AM
(162.6 ± 52.1 pg/lg of total protein), and LNCaP-trans-
fected cells had also high levels of secreted AM
(93.09 ± 9.08 pg/lg protein).Table 2
RIA analysis for hAM of the culture media of PC-3, DU 145, LNCaP,
and their cell transfectants
Cell line Clone hAM (pg/lg protein)
PC-3 PC-3 0.047 ± 0.005
Mock2 0.030 ± 0.001
hAM22 1.030 ± 0.032
hAM31 2.529 ± 1.16
hAM32 162.6 ± 52.1
DU 145 DU 145 0.547 ± 0.172
Mock2 0.780 ± 0.273
hAM5 1.166 ± 0.320
hAM6 7.440 ± 0.093
hAM9 7.446 ± 0.521
LNCaP LNCaP 1.41 ± 0.80
Mock 3.24 ± 0.14
hAM 93.09 ± 9.08AM inhibits PC-3 and LNCaP prostate cancer cell
proliferation
To study the eﬀect of AM overexpression in prostate
cancer cells, MTT proliferation assays were conducted.
As seen in Fig. 2, PC-3 (Fig. 2A) and LNCaP (Fig.
2B) cells transfected with AM signiﬁcantly reduced
(p < 0.01) their in vitro proliferation rates compared to
controls. In contrast, cell proliferation in DU 145 clones
overexpressing hAM was not signiﬁcantly altered
(p = 0.652) with respect to controls (Fig. 2C). Prolifera-
tion was also studied in PC-3 parental cells cultured in
the presence of conditioned media from PC-3-trans-
fected clones (Fig. 2D). Culture of PC-3 with superna-
tants from hAM22 and hAM31 for 4 days did not
result in a signiﬁcant cell growth inhibition compared
to controls (p = 0.05). However, culture of PC-3 cells
with supernatants from hAM32 (the clone with the high-
est expression and secretion of AM) for 4 days caused a
dramatic cell growth inhibition (p < 0.001) (Fig. 2D).
The inhibitory eﬀect of AM was further conﬁrmed by
addition of synthetic AM peptide to the parental pros-
tate cancer cells (Fig. 3A). Addition of hAM at concen-
trations ranging from 10 to 1000 nM produced a very
signiﬁcant reduction (p < 0.01) of cell proliferation in a
dose-dependent manner (up to 20% decrease for PC-3
and 50% for LNCaP). Lower concentrations (0.1 and
1 nM) did not cause such an eﬀect. In the case of DU
145, only the highest concentration of AM (1000 nM)
produced signiﬁcant (p < 0.05) cell growth inhibition
(Fig. 3A).
Fig. 2. Proliferation assays (MTTs) for the prostate cancer cell lines studies. (A) AM-overexpressing clones (hAM22, hAM31, and hAM32) show a
signiﬁcant decrease (**p < 0.01) in cell proliferation compared to controls (PC-3 and Mock2). (B) LNCaP cells overexpressing AM (transient
transfection) also show signiﬁcant reduction (**p < 0.01) in cell proliferation compared to mock-transfected cells. (C) Proliferation rates of DU 145
cells overexpressing AM (hAM6) are similar to those of controls (DU 145 and Mock1). (D) Parental PC-3 cells cultured for 4 days in the presence of
supernatants from hAM31, and hAM22 had slightly lower proliferation rates (non-signiﬁcant) than PC-3 cells cultured in the presence of
supernatants from controls (parental PC-3 and Mock2). However, PC-3 cells cultured in the presence of supernatants from hAM32 (the clone with
the highest secretion of AM) resulted in a dramatic cell growth inhibition (***p < 0.001). Data were analyzed by ANOVA for (A,C,D), and by
Students t test for (C). Each experiment was repeated at least three times.
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leads to cell growth retardation in anchorage indepen-
dent conditions (Fig. 3B). These experiments were con-
ducted for PC-3 and DU 145 cells. Quantiﬁcation by
image analysis revealed that PC-3 clones overexpressing
AM (hAM22, hAM31, and hAM32) suﬀered a signiﬁ-
cant decrease (p < 0.01, 60% reduction, approximately,
for hAM32) in the average area occupied by the colonies
compared to controls (parental PC-3 and Mock2) (Fig.
3B). In contrast, and in keeping with our MTT results,
the area occupied by the DU 145 cell clones hAM5,
hAM6, and hAM9 (which overexpress AM) did not dif-
fer from controls (result not shown).
Cell cycle analysis was performed in parental and
transfected PC-3 cells to determine whether overexpres-
sion of AM caused cell cycle arrest. In PC-3 and Mock2-
transfected cells, the percentage of cells in the diﬀerent
phases of the cell cycle was similar (Fig. 3C). However,
in the clones transfected with AM (hAM31 and
hAM32), there was a signiﬁcant increase in the percent-
age of cells in the G0/G1 phase, and a signiﬁcant de-
crease in the S and G2/M phases (p = 0.02) (Fig. 3C).
AM inhibits PC-3 tumorigenesis in nude mice
To evaluate the eﬀect of AM overexpression in vivo
we inoculated clones Mock2, hAM31, and hAM32 intonude mice (Fig. 3D). Five weeks after subcutaneous
injection, tumors reached an average volume of
800 mm3 for controls. Tumor growth was signiﬁcantly
reduced (by 50%, approximately, p = 0.013) when clones
hAM31 and hAM32 were injected, compared to con-
trols. These results conﬁrm our in vitro data and demon-
strate that overexpression of AM leads to cell growth
inhibition and decrease in tumorigenicity.
Postate cancer cells express AM receptors
Expression of the AM receptor complex CL/RCP/
RAMP was analyzed by RT-PCR (Fig. 4). All of the
prostate cell lines tested expressed the 497 bp band cor-
responding to CL, and the 196 bp band for RCP.
RAMP-1 was only detected in LNCaP cells (in both
controls and AM-transfected cells). The normal human
bronchiolar epithelium (NHBE) derived cDNA was
used as a control for RAMP-1. All of the prostate cell
lines showed the band with the expected size for
RAMP-2 (283 bp).
AM does not increase cAMP levels in PC-3, LNCaP, or
DU 145 cells, but aﬀects the MAPK pathway
AM signalling pathway in many cellular systems has
been linked to intracellular elevation of cAMP. For this
Fig. 3. (A) MTT proliferation assays in parental cell lines with diﬀerent concentrations of hAM in the culture medium. Cell proliferation is
signiﬁcantly decreased (**p < 0.01) in LNCaP and PC-3 cells at hAM concentrations ranging from 10 to 1000 nM, with respect to controls. On the
contrary, cell proliferation is only signiﬁcantly reduced (*p < 0.05) in DU 145 with concentrations of 1000 nM of AM. (B) Cell growth in anchorage-
independent conditions. PC-3 cell clones overexpressing AM have a signiﬁcantly reduced (*p < 0.01) anchorage-independent growth (as revealed by
the total area occupied by the colonies) than controls. (C) Cell cycle analysis shows that in the clones transfected with AM (hAM31 and hAM32)
there is a signiﬁcant increase in the percentage of cells in the G0/G1 phase, and a decrease in the percentage of cells in the S and G2/M phases
(*p = 0.02). (D) Tumor volume in nude mice is signiﬁcantly lower (*p = 0.013) when the injected cells overexpress AM (clones hAM31 and hAM32)
instead of controls (Mock2). Data were analyzed by ANOVA. The in vitro experiments (A,B,C) were repeated at least three times. The in vivo
experiment (D) was performed with 5 mice per group.
Fig. 4. Expression of AM receptors by RT-PCR. CL and RCP is
expressed in PC-3, DU 145, and LNCaP cells and their transfected (T)
clones. RAMP-1 is only expressed in LNCaP parental and transfected
cells. RAMP-2 is detected in PC-3, DU 145, and LNCaP cells and their
transfected clones. b-Actin served as an internal control. PCRs were
performed at least three times.
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on cAMP levels in prostate cancer cells. Total cAMP
levels were not altered in PC-3, DU 145, and LNCaP
parental cells after AM stimulation, regardless of the
AM dose or exposure time (results for PC-3 cells are
shown in Figs. 5A and B).
Since AM stimulation has also been related to
changes in the MAPK signalling cascade in some cell
types, ERK1/2 levels were analyzed in PC-3 cells.
Fig. 5C shows the increase in phosphorylated ERK1/
2 levels, 5 min after AM stimulation (which was main-
tained up to 20 min after the treatment). However,
long-term AM stimulation (longer than 40 min) re-
sulted in a decrease in phosphorylated ERK1/2. Treat-
ments for 1 h reduced phosphorylated ERK1/2 below
control levels. In AM-overexpressing cells, decrease in
phosphorylated ERK1/2 levels was dramatic compared
to controls (Fig. 5D). These results show that long-term
Fig. 5. Intracellular signalling of AM action. (A) PC-3 cells treated with diﬀerent concentrations of hAM (10 min after incubation) show no change
in cAMP levels. (B) PC-3 cells in a time-course experiment after hAM stimulation (1 nM) show no change in cAMP levels either. (C) Treatment of
PC-3 cells for 5–20 min causes an increase in phosphorylated ERK1/2, whereas longer treatments (40–60 min) produce a decrease of such levels
compared to untreated cells. Total ERK1/2 levels are not aﬀected. (D) PC-3 clones overexpressing AM (hAM32, transfected with hAM; or AM15
transfected with rAM) show reduced phosphorylated ERK1/2 levels, as compared to controls (parental PC-3 cells). Total ERK remains similar to
controls in the transfected cells. b-Actin served as loading control. Data for (A,B) were analyzed by ANOVA. All experiments were repeated three
times.
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lated ERK1/2.Discussion
Adrenomedullin is expressed in a variety of tissues
and cancer cells, including prostate [3,6,7]. However,
its role in prostate carcinogenesis is still poorly under-
stood. Previous studies have shown that AM can either
stimulate or inhibit cell growth, depending upon the cell
type [6,7,15,21]. We have analyzed the eﬀect of AM
stimulation and AM overexpression in PC-3, LNCaP,
and DU 145 cell lines. For PC-3 and DU 145 cells, we
were able to obtain stable cell clones overexpressing
AM, whereas for LNCaP, AM expression was shut
down approximately 1 week after transfections, proba-
bly due to silencing of the expression vector. Therefore,
transient transfections were used for experiments with
LNCaP. This approach has allowed us to have prostate
cells that produce high and constant levels of AM
mRNA and protein, which are secreted into the culture
medium.
MTT experiments in cells overexpressing AM have
shown a signiﬁcant cell growth inhibition in PC-3 and
LNCaP cells. These results were corroborated by the
addition of the hAM peptide to the culture medium.
In contrast, proliferation is not decreased in DU 145
clones overexpressing AM, and only addition of high
concentrations of hAM in the culture medium reducedproliferation of parental DU 145 cells. This result shows
that DU 145 is refractory to the AM inhibitory eﬀect ob-
served in PC-3 and LNCaP cells. We have analyzed with
further experiments the inhibitory eﬀect of AM in PC-3
cells overexpressing hAM. Cell cycle analysis, anchorage
independent growth assays, and culture of parental PC-
3 cells with supernatants from AM-transfected clones
conﬁrmed cell growth inhibition and cell cycle arrest at
the G0/G1 phase in vitro. Moreover, we have shown
in in vivo assays on nude mice that AM reduces signif-
icantly tumor growth. Our previous results overexpress-
ing rat AM in PC-3 cells are in keeping with our present
results [16].
Rocchi et al. [4], studied proliferation of PC-3,
LNCaP, and DU 145 cells after AM stimulation. These
authors describe no eﬀect in PC-3 and LNCaP cells, and
a slight increase in cell growth in DU 145 cells after
treatment with 2 · 107 M AM for 8 days. Although
these results are in disagreement with ours, the experi-
mental conditions were diﬀerent. Those authors used
serum-free TIS (transferrin, insulin, selenite) medium.
In our experience, these conditions make prostate cells
grow under stress and very slowly. This is probably
the reason why they needed the proliferation assays to
last for so long (8 days). Instead, we have used 1%
FCS, which is the lowest amount of serum needed for
the prostate cells to grow without stressful conditions
(unpublished observations). Interestingly, Martı´nez
et al. [21] have shown that the eﬀect of AM on mam-
mary cancer cell growth is critically dependent upon
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cells cultured in the presence of serum grew at lower
rates than control cells, whereas under stress conditions
(without serum), proliferation rates were increased [21].
AM also demonstrated to have an anti-apoptotic role in
T47D cells cultured in serum deprived medium or
TNF-a treatment. This result correlated with a de-
creased expression of pro-apoptotic molecules, such as
Bax, Bid, and caspase-8, in T47D cell clones overex-
pressing AM [21]. Similarly, treatment of VSMC cells
with AM results in cell growth inhibition or prolifera-
tion, depending on the presence or absence of serum
[15]. Thus, AM has a mitogenic eﬀect in VSMC cells
grown under stress conditions (serum deprivation),
whereas it exerts an anti-mitogenic eﬀect when cells
are grown with serum [15]. In our unpublished experi-
ments using prostate cancer cells in culture medium con-
taining TIS instead of serum, we did not ﬁnd a cell
growth inhibitory eﬀect after AM stimulation (in agree-
ment with Rocchi et al. [4]). All these considerations
point out that stressful culture conditions can alter cell
response to AM. This issue, which was suggested by
Martı´nez et al. [21], should be taken into consideration
for further proliferation assays and to re-evaluate previ-
ous controversial cell growth results after AM
stimulation.
PC-3, LNCaP, DU 145, and their AM-overexpress-
ing clones express the receptor complex CL/RCP/
RAMP-2. In addition, LNCaP cells express RAMP-1.
This result suggests that prostate cancer cells can pro-
duce and secrete AM into the culture media and be
responsive to the peptide through an autocrine/para-
crine mechanism. The presence of both AM and AM-re-
ceptors has been found in many other cell lines, such as
glioblastoma [22], zona glomerulosa cells [23], hepatic
stellate cells [24], and VSMC [15]. Therefore, an AM-
mediated autocrine or paracrine activation loop is prob-
ably a very common way of action [25].
The elevation of cAMP has been described as the
most common intracellular signalling process that oc-
curs after activation of AM receptors [6]. However,
other alternative intracellular pathways have been de-
scribed. These include increase in Ca+2 levels, elevation
of NO and cGMP, or modiﬁcation of MAPK levels,
especially ERK [6,14]. Our experiments show that the
elevation of cAMP is not responsible for the eﬀect ob-
served in prostate cells due to AM stimulation. Treat-
ment of cells with diﬀerent doses of AM or exposure
times showed no change in cAMP levels. Since MAPK
pathways are related to cell proliferation and AM sig-
nalling led to signiﬁcant cell growth inhibition in our
study, we decided to analyze ERK1/2 levels. We have
found that, indeed, AM treatment alters phosphorylated
ERK1/2 levels. However, the response is diﬀerent
depending on the time after stimulation. Short-term
stimulation (within 20 min) produces an increase inphospho-ERK, whereas long-term treatment leads to
decreased levels of phosphorylated ERK1/2. Moreover,
cell clones overexpressing AM, which have a sustained
high expression of the peptide, show very low levels of
phosphorylated ERK1/2 compared to control cells.
Experiments by other groups in diﬀerent cell lines have
shown variations in ERK levels after AM stimulation
[14,15,26,27]. It is a common ﬁnding that when AM
stimulates proliferation, levels of activated ERK in-
crease, and when AM inhibits proliferation, levels of
activated ERK decrease [14,15,26,27], which is coinci-
dent with our results.
The mechanism by which AM alters ERK levels is
still unknown. Both pathways involving G-protein cou-
pled receptors and tyrosine kinase receptors could be
responsible. In this regard, the existence of a still
uncharacterized tyrosine kinase receptor for AM has
been suggested [14]. In VSMC cells, growth eﬀects elic-
ited by AM are independent of cAMP levels and lead
to the activation of ERK [15]. This scenario could be
similar to what happens in prostate cancer cells, since
cAMP levels are not modiﬁed but active ERK levels
are decreased, under the eﬀect of AM. Further studies
are needed to elucidate how AM exerts its eﬀects in dif-
ferent cell types, including prostate cancer cells.
In conclusion, we demonstrate that hAM decreases
cell proliferation in PC-3 and LNCaP cells both in vitro
and in vivo. This eﬀect is likely due to an autocrine
mechanism which is independent of cAMP increase. Sig-
nalling pathways involve the alteration of MAPKs by
decreasing phosphorylated levels of ERK1/2 as a conse-
quence of AM stimulation.Acknowledgments
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